Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice

Invasion and Metastasis

Volumn 16, Issue 3, 1996, Pages 116-131

  Stearns, Mark E ^a   Wang, Min ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alendronate; Bone metastases; Prostate cancer; Taxol

Indexed keywords

ALENDRONIC ACID; MATRIX METALLOPROTEINASE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CARCINOGENESIS; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; ENZYME SYNTHESIS; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERITONEUM; SCID MOUSE; SOFT TISSUE; SURVIVAL RATE;

ALENDRONATE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; LUMBAR VERTEBRAE; MALE; METALLOENDOPEPTIDASES; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0030429781     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Fleisch H: Bisphosphonates - History and experimental basis. Bone 1987;8(suppl):523-528.
2. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
3. Smith R, Russel RGG, Bishop M: Diphosphonates and Paget's disease of bone. Lancet 1971;i:945-947.
4. Meunier PJ, Alexandre C, Edouard C, Mathieu L, Chapuy MC, Bressot C, Vignon E, Trechsel E: Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 1979;i:489-492.
5. Frijlink WB, Bijvoet OLM, de Veide J, Heynen G: Treatment of Paget's disease with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD). Lancet 1979;i:799-803.
6. Russel RGG, Smith R, Preston CJ, Walton RS, Woods CG: Diphosphonates in Paget's disease. Lancet 1974;i:894-898.
7. Canfield R, Rosner W, Skinner J, McWhorter J, Resnick L, Feldman F, Kammermans S, Ryan J, Kunigonis M, Bohne W: Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 1977;44:96-106.
8. Douglas DL, Tuckworth T, Russell RGG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS: Effect of dichloromethylene diphosphonate on Paget's disease of bone and hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980;1:1043-1047.
9. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij L, Bijvoet OLM: Paget's disease of bone: Early and late response to three different modes of treatment with aminohydroxy-propylidene bisphosphonate (APD). Br Med J 1987;295:1301-1305.
10. Pedrazzoni M, Palunvmeri E, Ciotti G, Davolli L, Pioli G, Girasole G, Passeri M: Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone. Bone Miner 1989;7:301-307.
11. Stone MD, Hawthrone AB, Kerr D, Webster G, Hosking DJ: Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD). J Bone Miner Res 1990;5:1231-1235.
12. O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NAT, Beneton MNC, Harris S, Mian M, Kanis JA: Treatment of Paget's disease of bone with amino-hydroxybutylidene bisphosphonate. J Bone Miner Res 1990;5:483-491.
13. Adami S: Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int 1986;39:226-233.
14. Van Holten-Verzantvoort A, Bijvoet OLM, Cleton FJ, Termans J, Kroon HM, Harinck HIT, Vermey P, Elte JWF, Neijt JP, Beex LVAM, Blijham GG: Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987;ii:983-985.
15. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. Br Med J 1988;297:772-773.
16. Elomaa I, Blomquist C, Porkka L, Holmstrom T, Taube T, Lamberg-Allardt C, Borgstrom GH: Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 1988;42:111-116.
17. Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E: Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990;3:23-30.
18. Attardo-Parrinello G, Merlini G, Pavesi F, Fiorentini ML, Ascari E: Effects of a new aminodiphosphonate in patients with osteolytic lesions from metastases and myelomatosis. Arch Intern Med 1987;147:1629-1633.
19. Hall DG, Stoica G: Effect of the bisphosphonate risedronate on bone metastases in rat mammary adenocarcinoma model system. J Bone Miner Res 1994;9:221-230.
20. Fleisch J, Russell RGG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
21. Galasko CSB: Development of skeletal metastases; in Galasko CSB (ed): Skeletal Metastases. Boston, Butterworth, 1986, pp 22-51.
22. Berrettoni BA, Carter JR: Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986;68:308-312.
23. Martin TJ, Mundy GR: Hypercalcemia of malignancy; in Martin TJ, Raisz LG (eds): Clinical Endocrinology of Calcium Metabolism. New York, Dekker, 1987, pp 171-199.
24. Orr W, Varani J, Gondek MD, Wark PA, Mundy GR: Chemotactic responses of tumor cells to products of resorbing bone. Science 1979;203:176-179.
25. Manishen WJ, Sivananthan K, Orr FW: Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Pathol 1986;123:39-45.
26. Elte JWF, Bijvoet OLM, Cleton FJ, Van Oosterom AT, Sleeboom HP: Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986;22:493-500.
27. Cleton FJ, van Holten-Verzantvoort AT, Bijvoet OLM: Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results Cancer Res 1989;116:73-78.
28. Fitton A, McTavish D: Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41/2:289-318.
29. Thiebaud D, Leyvraz S, von Fliedner V, Perey L, Cornu P, Thiebaud S, Burckhardt P: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991;27/1:37-41.
30. Guaitani A, Sabatini M, Polentarutti N, Filippeschi S, Marmonti L, Antonacci MD, Coccioli G, Bartosek I, Garattini S, Mantovani A: Effects of disodium etidronate on tumor-induced hypercalcemia, bone invasion, and metastasis in rodents; in Garattini S (ed): Bone Resorption, Metastasis, and Diphosphonates. New York, Raven Press 1985, pp 51-58.
31. Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ: Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res 1984;44:3007-3011.
32. Nemoto R, Satou S, Miyagawa I, Koiso K: Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. Cancer 1991;67:643-648.
33. Shevrin DH, Gorny KI, Rosol TJ, Kukreja SC: Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Prostate 1991;19:149-154.
34. Clarke NW, McClure J, George NJ: Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992;69:64-70.
35. Averbuch SD: New bisphosphonates in the treatment of bone metastases. Cancer 1993;72:3443-3452.
36. Einzig AI: A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991;9:59-64.
37. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259.
38. Weiss RB: Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-1268.
39. Grem JL: Phase I study of taxol administered as a short IV infusion daily for 5 days. Cancer Treat Rep 1987;71:1179-1189.
40. Donehower RC, Rowinsky EK, Cerochow LB, Longnecker SM, Ettinger DS: Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-1177.
41. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi ON: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
42. Wang M, Stearns ME: Isolation and characterization of 3 PC-3 human-prostatic tumor sublines which preferentially metastasize to select organs in SCID mice. Differentiation 1991;48:115-125.
43. Stearns ME, Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992;52:3776-3781.
44. Stearns ME: Taxol reduces circulating tumor cells to prevent bone metastasis in SCID mice. Invasion Metastasis, in press.
45. Stearns ME, Wang M, Fudge K: Liarozole and 13 Cis-retinoic acid's anti-prostatic tumor activity. Cancer Res 1993;53:3073-3078.
46. Horwitz SB, Parness J, Schiff PB, Manfredi JJ: Taxol: A new probe for studying the structure and function of microtubules. Cold Spring Harb Symp Quant Biol 1982;46:219-226.
47. De Brabander M, Geuens G, Nuydens R, Willebrords R, De May J: Microtubule stability and assembly in living cells: The influence of metabolic inhibitors, taxol and pH. Cold Spring Harb Symp Quant Biol 1982;46:227-240.
48. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc Natl Acad Sci USA 1996;93:3068-3073.
49. Kostenuik PJ, Orr FW, Suyama K, Singh G: Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 1993;53:5452-5457.
50. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human cancer burden in nude mice. Cancer Res 1995;55:3551-3557.